Aslan Pharmaceuticals (ASLN) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Aslan Pharmaceuticals has initiated voluntary liquidation for its main operating subsidiary after a strategic review, leading to the termination of all employees. The company, facing delisting from the Nasdaq due to non-compliance with listing requirements, has appointed Quantuma (Singapore) as the liquidator to explore strategic alternatives for its key assets, eblasakimab and farudodstat, while also preparing to liquidate under Cayman law.
For further insights into ASLN stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money